TICKERNERD
Menu
SLPSLPHealthcare · Health Information Services

SLP Stock Forecast: Simulations Plus, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$18
+0.11% on the day

The 5 Wall Street analysts covering Simulations Plus, Inc. hold a median 12-month price target of $17 — -6.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$372.1M
Ticker Nerd rank
91 / 100
Median analyst target
$17
Analysts covering
5
Total return, dividends reinvested
1W
+0.3%
1M
+0.9%
YTD
+0.9%
1Y
+33.6%
From 52W high
−11.7%
From 52W low
+62.0%
$11
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SLP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Simulations Plus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Growth
87
Issuance
69
Momentum
69
Quality
66
Value
65
Revisions
60
Size
58
Volatility
43

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (43): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SLP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20$22Oct 25Jan 26Apr 26Jul 26SLPHigh $19Median $17Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
0 Buy5 Hold0 Sell
Low $16Median $17High $19

The green dot is the last close — the median target sits −6.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 June 2026William BlairDowngradeMarket Perform—
10 Apr 2026TD CowenMaintainsHold—
8 Jan 2026TD CowenMaintainsHold—
18 Dec 2025BTIGDowngradeNeutral—
30 Sept 2025TD CowenInitiatesHold—
15 July 2025KeybancDowngradeSector Weight—
15 July 2025Stephens & Co.MaintainsOverweight—
14 July 2025KeybancMaintainsOverweight—
7 July 2025BTIGMaintainsBuy—
18 June 2025JMP SecuritiesReiteratesMarket Perform—
13 June 2025Craig-HallumMaintainsBuy—
16 Apr 2025KeybancMaintainsOverweight—
24 Jan 2025KeybancMaintainsOverweight—
8 Jan 2025KeybancMaintainsOverweight—
15 Nov 2024Stephens & Co.InitiatesOverweight—
6 Nov 2024William BlairReiteratesOutperform—
24 Oct 2024BTIGMaintainsBuy—
24 Oct 2024William BlairReiteratesOutperform—
12 Sept 2024William BlairReiteratesOutperform—
29 July 2024KeybancInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SLP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
0.0%
Analysts raising
1
Analysts cutting
5
Fundamentals

Simulations Plus, Inc. (SLP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
46.0×

Cheaper than 16% of US stocks

Price / sales
4.5×

Cheaper than 28% of US stocks

Price / book
2.7×

Cheaper than 38% of US stocks

EV / EBITDA
21.5×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
7.5%

Higher than 45% of US stocks

Earnings growth (YoY)
7.5%

Higher than 45% of US stocks

Gross margin
69.1%

Higher than 82% of US stocks

Operating margin
22.8%

Higher than 82% of US stocks

Net margin
9.9%

Higher than 69% of US stocks

Returns & dividend
Return on equity
6.2%

Higher than 55% of US stocks

Return on assets
5.5%

Higher than 79% of US stocks

Dividend yield
1.3%

Higher than 32% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SLP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
SLPSimulations Plus, Inc.$372.1M
91
CARLCarlsmed, Inc.$436.3M
22
NRCNRC Health$500.1M
87
EVHEvolent Health, Inc.$529.2M
63
WEAVWeave Communications, Inc.$583.2M
79
CTEVClaritev Corp.$614.0M
64
SPOKSpok Holdings, Inc.$212.4M
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Simulations Plus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLP news & analysis

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

GlobeNewsWire · 20 Aug 2026negative

Johnson Fistel, PLLP announced it is investigating Simulations Plus, Inc. for investors who suffered losses and whether they may recover under federal securities laws, following a revenue guidance cut and accounting disclosures. The investigation notes that on April 3, 2025, Simulations Plus reported its Q2 fiscal 2025 financial results and maintained full-year revenue guidance of $90 million to $93 million.

Why it matters — A law firm investigation tied to revenue guidance cuts and accounting disclosures could signal potential legal or regulatory concerns for SLP investors.

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

Business Wire · 13 Aug 2026positive

Simulations Plus announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired in connection with its pending acquisition by Altaris, LLC. This expiration satisfies one of the regulatory conditions related to the previously announced acquisition.

Why it matters — The expiration of the HSR waiting period marks progress toward completing the regulatory steps for the pending Altaris acquisition, a key development for Simulations Plus shareholders.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

GlobeNewsWire · 6 Aug 2026negative

Johnson Fistel, PLLP announced it is investigating Simulations Plus on behalf of investors who suffered losses, following the company's revenue guidance cut and accounting disclosures. The firm is examining whether those losses may be recoverable under federal securities laws.

Why it matters — A securities investigation tied to a revenue guidance cut and accounting disclosures signals potential legal exposure for Simulations Plus, which an SLP watcher would want to track.

Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

Business Wire · 30 July 2026negative

A law firm, Kahn Swick & Foti, is investigating the proposed sale of Simulations Plus to affiliates of Altaris, LLC for $18.50 per share, seeking to determine whether the consideration and sale process are adequate.

Why it matters — The investigation introduces uncertainty about whether the proposed buyout price and process fairly serve shareholder interests.

Simulation Plus, Inc. Securities Fraud Investigation - Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws

Newsfile Corp · 29 July 2026negative

Robbins LLP has announced it is investigating Simulation Plus, Inc. for possible violations of securities laws concerning false or misleading statements related to its financial reporting, internal controls, and business outlook. The investigation seeks to determine whether certain officers or directors breached fiduciary duties owed to shareholders.

Why it matters — A securities fraud investigation raises serious questions about the accuracy of Simulation Plus's past financial disclosures and internal controls, which could affect investor confidence and expose the company to legal liabilities.

FAQ

Frequently asked questions about SLP stock

What is the SLP stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Simulations Plus, Inc. have a median 12-month price target of $17, with estimates ranging from $16 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLP stock a buy right now?

Of the 5 analysts covering Simulations Plus, Inc., 0 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Simulations Plus, Inc. 91 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLP?

As at 22 Aug 2026, Simulations Plus, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

Will SLP stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -6.2% from the last close, and Ticker Nerd's factor model ranks Simulations Plus, Inc. 91 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLP stock forecast for 2030?

No analyst covering Simulations Plus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $19 over the next 12 months.

How has SLP stock performed over the past year?

Simulations Plus, Inc. returned +33.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Simulations Plus, Inc. do?

Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and related industries.

What is the latest news on SLP?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures". Johnson Fistel, PLLP announced it is investigating Simulations Plus, Inc. for investors who suffered losses and whether they may recover under federal securities laws, following a revenue guidance cut and accounting disclosures. The investigation notes that on April 3, 2025, Simulations Plus reported its Q2 fiscal 2025 financial results and maintained full-year revenue guidance of $90 million to $93 million.

Company

About Simulations Plus, Inc.

Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services for the pharmaceutical, biotechnology, and related industries. The company develops advanced tools such as GastroPlus for physiologically based pharmacokinetic modeling and simulation of drug absorption, DDDPlus for in vitro dissolution testing, MembranePlus for biopharmaceutical experiments, ADMET Predictor for molecular property prediction and AI-driven drug design, MonolixSuite for pharmacometrics analysis, DILIsym for quantitative systems toxicology, Thales for quantitative systems pharmacology, and Pro-ficiency for performance management in training. These solutions support drug discovery, development, preclinical and clinical trial data analysis, regulatory submissions, and areas like ADMET prediction, safety assessment, and treatment regimen optimization. Simulations Plus also offers expert consulting in pharmacometrics, PBPK modeling, and regulatory interactions, serving major pharmaceutical, biotech, agrochemical, chemical, and consumer goods companies worldwide. Founded in 1996 and headquartered in Lancaster, California, the company plays a key role in accelerating model-informed drug development and enhancing R&D efficiency across the biopharma sector.

212 employees · United States · https://www.simulations-plus.com